Aim: The main treatment for meibomian gland dysfunction (MGD), a major cause of dry eye, is eyelid warming. Lack of compliance is the main reason for treatment failure. This has led to the development of eyelid-warming devices that are safe, effective and convenient. To obtain robust evidence demonstrating their efficacy, the authors conducted a 3-arm randomized clinical study.
INTRODUCTION
Dry eye is a common condition with symptoms that impact patients' quality of life [1, 2] . It is perceived to be as distressing as chest pain [3] and imposes considerable healthcare costs, up to US$1.1 million per 1,000 persons annually [4] , and productivity costs [1] . Meibomian gland dysfunction (MGD) is a chronic abnormality of the meibomian glands (MGs) [5] . It may cause eye discomfort [6] and affect tear film stability [5] which leads to poorer visual function, faster tear evaporation and ocular surface damage [7] . MGD is thought to be a major cause of dry eye that affects 46.2-69.3% Asians and 3.5-19.9%
Caucasians [8] [9] [10] . The cornerstone therapy for MGD is warm compress [11] . Various forms of eyelid-warming therapy have been shown to improve patients' symptoms [12] [13] [14] [15] [16] [17] [18] [19] , tear film stability [12] [13] [14] [15] [16] [17] [18] , slow down tear evaporation [14] and reduce ocular surface damage [18, 20] . Other additional treatments such as lubricating drops, antibiotics, anti-inflammatory cyclosporine and topical azithromycin are prescribed for more severe MGD [11] .
The recommended regimen for warm compress is daily treatment [11] . This is prone to poor compliance and difficulty in delivering therapeutic temperatures [21] . Several eyelidwarming devices with features that improve convenience and deliver heat at safe, calibrated temperatures to the eyelids have been developed recently [15, 22] [16] show effects of short-term (up to 3 weeks) studies, or after just one application of the device. Two articles [20, 22] 
METHODS

Study Design and Participants
This is a 3-month randomized, controlled trial comparing two eyelid-warming devices, EyeGiene Ò and Blephasteam Ò , and warm towel compress in MGD participants.
From February 2012 to October 2013, all patients at the Singapore National Eye Centre dry eye clinic who met the eligibility criteria were briefed about this study and invited for screening. The MGD in this study is not classified into severity levels but as long as the morphological eligibility criterion below and specified symptoms are present, they can be included. Eligible participants were then enrolled with written informed consent by the clinical trial coordinator.
Compliance with Ethics Guidelines
The study has been approved by the SingHealth • At least one MG opening with pouting and a visible plug above the eyelid margin that cannot be removed by gentle wiping with a cotton tip.
• No ocular pathology requiring treatment other than eye lubricant and conventional eyelid hygiene within the last month and during the study.
• Participants with data at baseline and 1 month after treatment.
These patients were excluded from the study:
• Known diagnosis of thyroid dysfunction and rheumatoid arthritis.
• Ocular surgery within the previous 6 months and laser-assisted in situ keratomileusis (LASIK) within the previous year.
• Central nervous system and hormonal drugs required within the last month and during the study.
• Active ocular infection or presence of pterygium.
• Necessity to wear contact lens during the study.
• Living in the same household as another participant of the study.
Randomization and Blinding
The nursing manager and two witnesses drew lots to determine the random allocation sequence of participants to the three treatment methods in a 1:1:1 ratio. The assessor of the participants' clinical signs was blinded to the treatment method of each participant.
Interventions
All participants were required to self-administer the eyelid-warming therapies twice daily, for 10 min each time, then briefly massage their eyes and clean their eyelids with Blephagel
Macclesfield, UK) and cotton pads.
Control Arm
Participants were given a towel to warm in warm water before placing it over their eyes.
They were instructed to re-warm the towel when they feel it get cooler. 
Compliance Measures and Concurrent
Medications
The participants were given a diary to record details of each treatment session (time and duration), eyelid cleaning with Blephagel Ò and use of eye lubricant. Participants were allowed to use eye lubricants but not antibiotics, steroid and anti-inflammatory eye drops such as cyclosporine as stipulated in the inclusion criteria.
Efficacy Outcome Measures
The primary efficacy outcome was the proportion of participants with improvement in severity and frequency of eye discomfort after 1 month of treatment. The secondary efficacy outcomes were the proportions of participants with improvement in symptom severity and frequency between 1 and 3 months of treatment. The symptom severity and frequency were performed on a visual analog scale as previously described [24] . The details of all the study procedures are provided in the supplementary file.
Safety Outcome
Adverse events (AEs) and serious adverse events (SAEs) were monitored but the pre-specified safety outcome was changed in VA after 3 months of treatment. This is because a previous study found VA to be affected by lid warming [25] .
Exploratory Efficacy Outcomes
Our exploratory outcomes were the changes in TBUT, number of plugged MG openings, corneal fluorescein staining and Schirmer's test after 1 and 3 months of treatment.
Statistical Analyses
Sample Size Calculation 
RESULTS
Of 102 patients who were assessed for eligibility, 75 were enrolled. Subsequently three patients were found to have a history of thyroid disease and were therefore considered not eligible. The other 72 patients were randomized into three equal groups ( Supplementary Fig. 2 ). Table 1 shows the patients (n = 65) who were successfully followed up and had data at 1 month (primary outcome analysis). The ages of these participants were 53. Table 2 ). The proportions with reduced severity at 1 month were 50.0%, 52.9% and 75.0%, respectively. There were no significant There was no significant difference among the three groups for change in TBUT at 1 month (p = 0.669; Table 4 ). After 3 months of treatment, there was also no significant difference in the change in TBUT (p = 0.612).
There was no significant change in Schirmers I, Marx's line score and meibum viscosity among the participants at 3 months (data not shown).
Although there was a significant decrease in the total number of plugged MG orifices (p\0.001) over 12 weeks, there was no significant difference among the three treatment groups after 1 month (p = 0.656) and 3 months of treatment (p = 0.926) ( Table 5 ).
All three eyelid-warming methods did not worsen participants' VA after 3 months of twicedaily treatment (p = 0.672, 0.769 and 0.900; Supplementary Table 4 ). There were two reports of unexpected AEs that were not related to study treatment. show any advantage over the warm towel but this could be due to either a lower symptom severity at baseline or reduced participation related to technical difficulty of using the device. All treatment modalities did not harm vision. patients' symptoms [17] [18] [19] . EyeGiene Ò , which has also been marketed as iHeat, relieved ocular symptoms in 56% participants in a previous 2-week study [15] . This study showed similar results, with *50% who improved after 1 month ( [20] and dry eye patients has been reported. This study, however, was interested in the longer-term effect of heat therapy on the eyes and showed no significant change of BCVA in MGD participants after 3 months of therapy. Villani et al. [17] reported significant improvement in TBUT after 3 weeks of Blephasteam Ò treatment but Doan et al. [19] disagreed. The majority of the Blephasteam Ò participants had increased TBUT after 1 and 3 months of treatment but this change in TBUT was not significantly different compared to warm towel or EyeGiene Ò participants (Table 4 ). There was no significant change in TBUT in a 2-week study of EyeGiene Ò treatment [15] . Instead of looking at just the change in TBUT with EyeGiene Ò treatment, the authors wanted to see if the change was different among the three treatment groups but it was not ( Table 2 ). The safety assessment of the Eyegiene Ò device may not be robust enough given reduced patient numbers analyzed.
Temperature for the towel was not specified and thus might defer from previously published studies. The study might not be generalizable to all MGD patients because our patients were predominantly Chinese. As participants could not be blinded, there might be some placebo-like effect affecting the results of the study.
Factors not covered in this report, possibly inflammation, meibum composition and MG atrophy can be associated with symptom improvement.
Besides understanding the factors predicting for treatment success, it would also be valuable to conduct pathological or imaging studies to understand the physiological or anatomical mechanism behind the recovery of MGD after eyelid-warming therapies. This trial also included the measurement of tear evaporation as well as meibography and laboratory investigations such as tear and meibum lipidomics analyses which will be presented in upcoming reports. 
CONCLUSION
